Key Takeaway: AC Immune has received FDA Fast Track Designation for its anti-alpha-synuclein immunotherapy, ACI-7104, aimed at treating early Parkinson's Disease. The company plans to expand its ongoing Phase 2 VacSYn study to additional sites in the USA following Investigational New Drug clearance. Recent interim results have shown promising safety outcomes.
Market Sentiment Analysis
POSITIVE FACTORS
FDA Fast Track Designation granted for ACI-7104.
Ongoing Phase 2 VacSYn study expanding to USA.
Recent interim results indicate safety.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+16%
120-day peak, hindsight
Typical move
6.6%
average across 8 past catalysts
Lead asset
ACI-7104.056 at Dose A
Phase 2 · Parkinson Disease
Full Press Release Details
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD) Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance Recent positive interim results showed safety and
Frequently Asked Questions
What is ACI-7104?
ACI-7104 is an anti-alpha-synuclein active immunotherapy developed by AC Immune.
What designation did ACI-7104 receive from the FDA?
ACI-7104 received FDA Fast Track Designation for treating early Parkinson's Disease.
What is the VacSYn study?
The VacSYn study is a Phase 2 clinical trial evaluating ACI-7104.
Where will the VacSYn study expand?
The VacSYn study will expand to additional sites in the USA.
What were the recent results of ACI-7104?
Recent interim results from the study indicated positive safety outcomes.